Dental Treatment Of Patients With Factor VIII Deficiency Who Developed Inhibitor

37572

Hemophilia A is the most common hereditary coagulation disorder, affecting 1/5000 males born live. In approximately 25% to 30% of patients with hemophilia A and in approximately 1% to 3% of the patients with hemophilia B inhibitors develop during their lifetime. A novel way to treat hemophilia patients with inhibitors is the administration of recombinant factor VIIa. Factor VIIa prolong clot lysis time in plazma and down regulate fibrinolysis via activation of trombin activatable fibrinonolysis inhibitor. In this report we present the successful dental treatment of one patient who have severe inhibitor to Factor VIII using recombinant Factor VIIa. Advantages of rFVIIa over traditional treatment (ie, factor concentrates) are the lack of antigenicity and viral safety. On the other hand that is more expensive than traditional treatment.

101

Hemophilia , Inhibitor , rFVIIa

Cumhuriyet Dental Journal

105

Cumhuriyet Dental Journal